Molecules and Cells

Korean Society for Molecular and Cellular Biology (한국분자세포생물학회)
권호 표지
DOI QR코드

DOI QR Code

IP-10 Expression in Patients with Chronic HBV Infection and Its Ability to Predict the Decrease in HBsAg Levels after Treatment with Entecavir

  • Zhao, Kai (Institute of Immunology, Taishan Medical University) ;
  • Yang, Tao (Research Centre for Biological Therapy, Institute of Translational Hepatology) ;
  • Sun, Mimi (Department of Liver Disease, the 88th Hospital of PLA) ;
  • Zhang, Wei (Department of Liver Disease, the 88th Hospital of PLA) ;
  • An, Yong (Department of Liver Disease, the 88th Hospital of PLA) ;
  • Chen, Gang (Department of Liver Disease, the 88th Hospital of PLA) ;
  • Jin, Lei (Research Centre for Biological Therapy, Institute of Translational Hepatology) ;
  • Shang, Qinghua (Department of Liver Disease, the 88th Hospital of PLA) ;
  • Song, Wengang (Institute of Immunology, Taishan Medical University)
  • Received : 2017.03.23
  • Accepted : 2017.05.11
  • Published : 2017.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Interferon-${\gamma}$-inducible protein 10 (IP-10), also known as chemokine C-X-C motif ligand (CXCL) 10, is closely associated with antiviral immunity and the progression of chronic hepatitis B (CHB). However, the value of baseline serological and histological IP-10 expression levels in predicting the efficacy of the antiviral response to nucleoside/nucleotide analogues (NAs) is still unknown. In our research, intrahepatic and peripheral IP-10 expression levels were systemically examined before and after treatment with entecavir (ETV). Baseline serological and histological IP-10 expression levels were significantly increased in patients with CHB, particularly in patients with higher degrees of liver inflammation and liver fibrosis. Moreover, higher baseline intrahepatic IP-10 levels indicated better prognoses in patients with CHB after entecavir therapy. The baseline IP-10 level was also positively associated with several clinical parameters, including baseline levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), hepatitis B virus (HBV) DNA, and hepatitis B surface antigen (HBsAg), and with the decrease in HBsAg levels after treatment. In addition, monocyte-derived IP-10 was expressed at higher levels in patients with CHB than in patients with liver cirrhosis (LC) and healthy controls (HC). According to the results of our in vitro experiments, IP-10 directly promoted hepatocyte apoptosis. Based on these findings, baseline serological and histological IP-10 levels might predict CHB severity and the decrease in HBsAg levels after entecavir therapy.

Keywords

References

  1. Deng, G., Zhou, G., Zhang, R., Zhai, Y., Zhao, W., Yan, Z., Deng, C., Yuan, X., Xu, B., Dong, X., et al. (2008). Regulatory polymorphisms in the promoter of CXCL10 gene and disease progression in male hepatitis B virus carriers. Gastroenterology 134, 716-726. https://doi.org/10.1053/j.gastro.2007.12.044
  2. Gong, L.-L., Zhao, B.-B., Fan, W.-F., Gong, L.-Y., Chen, C.-F., Liu, J.-J., and Lu, X. (2015). Correlations of IFN-${\gamma}$-inducible protein-10 with the risk of chronic hepatitis B and the efficacy of interferon therapy in Asians. Int. J. Clin. Exp. Pathol. 8, 8367-8375.
  3. Jaroszewicz, J., Ho, H., Markova, A., Deterding, K., Wursthorn, K., Schulz, S., Bock, C.T., Tillmann, H.L., Manns, M.P., Wedemeyer, H., et al. (2011). Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues. Antiviral Ther. 16, 915-924. https://doi.org/10.3851/IMP1866
  4. Sahin, H., Borkham-Kamphorst, E., do O, N.T., Berres, M.L., Kaldenbach, M., Schmitz, P., Weiskirchen, R., Liedtke, C., Streetz, K.L., Maedler, K., et al. (2013). Proapoptotic effects of the chemokine, CXCL 10 are mediated by the noncognate receptor TLR4 in hepatocytes. Hepatology 57, 797-805. https://doi.org/10.1002/hep.26069
  5. Scheuer, P.J. (1991). Classification of chronic viral hepatitis: a need for reassessment. J. Hepatol. 13, 372-374. https://doi.org/10.1016/0168-8278(91)90084-O
  6. Sevgi, D.Y., Bayraktar, B., Gunduz, A., Ozguven, B.Y., Togay, A., Bulut, E., Uzun, N., and Dokmetas, I. (2016). Serum soluble urokinase-type plasminogen activator receptor and interferongamma-induced protein 10 levels correlate with significant fibrosis in chronic hepatitis B. Wien. Klin. Wochenschr. 128, 28-33. https://doi.org/10.1007/s00508-015-0886-4
  7. Sonneveld, M.J., Arends, P., Boonstra, A., Hansen, B.E., and Janssen, H.L. (2013). Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B. J. Hepatol. 58, 898-903. https://doi.org/10.1016/j.jhep.2013.01.029
  8. Wang, Y., Zhao, C., Zhang, L., Yu, W., Shen, C., Wang, W., Zhen, Z., and Zhou, J. (2014). Predictive value of interferon-gamma inducible protein 10 kD for hepatitis B e antigen clearance and hepatitis B surface antigen decline during pegylated interferon alpha therapy in chronic hepatitis B patients. Antiviral Res. 103, 51-59. https://doi.org/10.1016/j.antiviral.2014.01.001
  9. Willemse, S.B., Jansen, L., de Niet, A., Sinnige, M.J., Takkenberg, R.B., Verheij, J., Kootstra, N.A., and Reesink, H.W. (2016). Intrahepatic IP-10 mRNA and plasma IP-10 levels as response marker for HBeAgpositive chronic hepatitis B patients treated with peginterferon and adefovir. Antiviral Res. 131, 148-155. https://doi.org/10.1016/j.antiviral.2016.05.002
  10. Wong, G.L., Chan, H.L., Chan, H.Y., Tse, C.H., Chim, A.M., Lo, A.O., and Wong, V.W. (2016). Serum interferon-inducible protein 10 levels predict hepatitis B s antigen seroclearance in patients with chronic hepatitis B. Aliment Pharmacol Ther. 43, 145-153. https://doi.org/10.1111/apt.13447
  11. Xu, R., Lin, F., He, J., Jin, L., Zhang, J.Y., Fu, J., Liu, H., Wang, S., Zhang, Z., and Wang, F.S. (2013). Complement 5a stimulates hepatic stellate cells in vitro, and is increased in the plasma of patients with chronic hepatitis B. Immunology 138, 228-234. https://doi.org/10.1111/imm.12024
  12. Yoshio, S., Sugiyama, M., Shoji, H., Mano, Y., Mita, E., Okamoto, T., Matsuura, Y., Okuno, A., Takikawa, O., Mizokami, M., et al. (2016). Indoleamine-2,3-dioxygenase as an effector and an indicator of protective immune responses in patients with acute hepatitis B. Hepatology 63, 83-94. https://doi.org/10.1002/hep.28282
  13. Zhang, J.Y., Zhang, Z., Lin, F., Zou, Z.S., Xu, R.N., Jin, L., Fu, J.L., Shi, F., Shi, M., Wang, H.F., et al. (2010). Interleukin-17-producing CD4(+) T cells increase with severity of liver damage in patients with chronic hepatitis B. Hepatology 51, 81-91. https://doi.org/10.1002/hep.23273
  14. Zhang, G., Chen, Y., BilalWaqar, A., Han, L., Jia, M., Xu, C., and Yu, Q. (2015). Quantitative analysis of rabbit coronary atherosclerosis. Practical techniques utilizing open-source software. Anal. Quant. Cytol. Histol. 37, 115-122.

Cited by

  1. Plasma Biomarkers of Human Immunodeficiency Virus-Related Systemic Inflammation and Immune Activation in Sub-Saharan Africa Before and During Suppressive Antiretroviral Therapy vol.220, pp.6, 2019, https://doi.org/10.1093/infdis/jiz252
  2. Soluble immune markers in the different phases of chronic hepatitis B virus infection vol.9, pp.1, 2019, https://doi.org/10.1038/s41598-019-50729-5
  3. Kupffer cells promote T-cell hepatitis by producing CXCL10 and limiting liver sinusoidal endothelial cell permeability vol.10, pp.16, 2020, https://doi.org/10.7150/thno.44960
  4. Current practice and contrasting views on discontinuation of nucleos(t)ide analog therapy in chronic hepatitis B vol.14, pp.4, 2017, https://doi.org/10.1080/17474124.2020.1738219
  5. Interferon-γ-Inducible Protein 10 (IP-10) Kinetics after Antiretroviral Treatment Initiation in Ethiopian Adults with HIV vol.9, pp.3, 2017, https://doi.org/10.1128/spectrum.01810-21